Short answer
Compass Therapeutics, Inc. (CMPX) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$27M
- −90.6% YoY · −8.0% QoQ
- EPS (diluted)
- −$0.15
- −87.5% YoY · −15.4% QoQ
Source: XBRL data from the Compass Therapeutics, Inc. (CMPX) Q3 2026 10-Q on SEC EDGAR. USD.
Compass Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no product sales generated
- Operating margin -107.0% vs -110.9% YoY, based on operating losses of $28.8 million and $15.8 million
- Tovecimig highest R&D spending, $14.4 million vs $3.3 million YoY
- Cash, equivalents and marketable securities $163 million, funding operations into 2028
- Operating cash use $48.3 million, up from $35.9 million YoY; FDA recommended survival-benefit trial before tovecimig BLA
Risk Factors
- New corporate-governance risk: bylaws adopted exclusive Delaware and Massachusetts forums for specified stockholder litigation
- Regulatory and legal risk: Securities Act claims restricted to U.S. District Courts in Delaware or Massachusetts
- Macroeconomic risk: July 2026 U.S. tariffs of approximately 10% to 12.5% increased potential research and development costs
- Operational risk: macroeconomic disruptions could delay clinical-trial initiation or expansion and material supply availability
- Financial risk: deteriorating equity and credit markets could make future financing costlier, more dilutive, or unavailable
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Compass Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.